London 2014 Registration Visa Letters Programme Satellite Meetings Glaucoma Day 2014 Exhibition Hotel Booking Virtual Exhibition Star Alliance
london escrs

Course handouts are now available
Click here

Come to London


WATCH to find out why

Site updates:

Programme Updates. Programme Overview and - Video Symposium on Challenging Cases now available.


Search Abstracts by author or title
(results will display both Free Papers & Poster)

Medium and long-term evaluation of visual outcomes following cataract surgery with implantation of Seelens multifocal intraocular lens (IOL)

Poster Details

First Author: G.Vizzari ITALY

Co Author(s):    P. Bordin              

Abstract Details


To evaluate the postoperative visual outcomes after cataract surgery in patients implanted with Seelens (Hanita Lenses, Hanita, Israel) multifocal IOL after more than 2 years of follow up.


Eye Clinic, Hospital of Legnago, Verona, Italy


The inclusion criteria of this study were: absence of ocular pathologies, bilateral cataract, astigmatism < 1,5 D, biometry (SRK-T formula) with IOL Master (Carl Zeiss AG, Feldbach, Switzerland). 110 eyes from 55 patients were evaluated in a cross-sectional study. Each patient underwent phacoemulsification and in-the-bag implantation of Seelens (Hanita Lenses,Hanita, Israel). Uncorrected distance visual acuity (UCDVA) were measured using a Snellen table. Uncorrected intermediate visual acuity (UCIVA) was assessed at 80 cm with a Snellen chart. Uncorrected near visual acuity (UCNVA) was obtained at 40 cm using a Jaeger chart.


After a mean follow-up period of 29  4.1 months, the mean UCDVA of the Seelens improved significantly after surgery changing from 0.47  0.16 to 0.91  0.11 (32% of the eyes achieved 1.0) (p<0.001), the mean UCIVA was of 0.89  0.16 and the mean UCNVA was 2.21  0.57 J, with 25.4% of the eyes attaining J1, and 37.2% J2.


The UCDVA improved significantly after surgery in all patients. The Seelens multifocal intraocular lens provided an excellent near visual outcomes, with 62.6% of the eyes achieving J2 or better without spectacle correction. FINANCIAL INTEREST: NONE

Back to Poster listing